澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ALGORAE PHARMACEUTICALS LTD

0.022

-0.001-4.35%

成交量：183.19萬

成交額：4.10萬

市值：3,715.27萬

市盈率：-44.09

高：0.023

開：0.023

低：0.022

收：0.023

52周最高：0.024

52周最低：0.005

股本：16.89億

流通股本：10.47億

量比：1.04

換手率：0.18%

股息：- -

股息率：- -

每股收益(TTM):0.000

每股收益(LYR):0.000

淨資產收益率：-30.63%

總資產收益率：-23.85%

市淨率：16.67

市盈率(LYR):-44.09

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Algorae製藥公司達成協議將在澳大利亞和新西蘭推出兩款心血管及代謝疾病仿製藥

Algorae Pharmaceuticals - 簽署協議向澳大利亞市場供應化療藥物卡培他濱

Algorae Pharmaceuticals - 擬議協議下，公司將在澳新市場推出兩款仿製藥及其他產品

Algorae Pharmaceuticals達成協議，將5款仿製腫瘤藥物推向澳大利亞和新西蘭市場

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/1AI.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"1AI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","market":"AU","secType":"STK","nameCN":"ALGORAE PHARMACEUTICALS LTD","latestPrice":0.022,"timestamp":1770613920000,"preClose":0.023,"halted":0,"volume":1831909,"delay":0,"changeRate":-0.04347826086956526,"nameEN":"ALGORAE PHARMACEUTICALS LTD","floatShares":1046585658,"shares":1688759058,"eps":-0.000499,"marketStatus":"已收盤","change":-0.001,"latestTime":"02-09 16:12:00 AEDT","open":0.023,"high":0.023,"low":0.022,"amount":40971,"amplitude":0.043478,"askPrice":0.023,"askSize":94123,"bidPrice":0.021,"bidSize":250572,"shortable":3,"etf":0,"ttmEps":-0.000499,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.023,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":1.039393,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","floatShares":1046585658,"roa":"-23.85%","roe":"-30.63%","lyrEps":-0.000499,"volumeRatio":1.039393,"shares":1688759058,"dividePrice":0,"high":0.023,"amplitude":0.043478,"preClose":0.023,"low":0.022,"week52Low":0.005,"pbRate":"16.67","psRate":"263.40","week52High":0.024,"institutionHeld":0,"latestPrice":0.022,"committee":0.453877,"eps":-0.000499,"divideRate":0,"volume":1831909,"delay":0,"ttmEps":-0.000499,"open":0.023,"prevYearClose":0.014,"prevWeekClose":0.023,"prevMonthClose":0.021,"prevQuarterClose":0.014,"fiveDayClose":0.02,"twentyDayClose":0.014,"sixtyDayClose":0.009,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/1AI.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"1AI.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"1AI.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1199700351","title":"Algorae製藥公司達成協議 將在澳大利亞和新西蘭推出兩款心血管及代謝疾病仿製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1199700351","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199700351?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 06:04","pubTimestamp":1770588254,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd宣布已签署一项重要合作协议，计划在澳大利亚与新西兰市场同步上市两款针对心血管疾病和代谢紊乱的通用名药物。\n此次战略布局将显著提升该公司在大洋洲医药市场的竞争力，通过提供高性价比的替代治疗方案，有望缓解当地患者长期用药的经济压力。两款药物的上市也将进一步完善Algorae在慢性病治疗领域的产品矩阵。\n业内人士分析，此次合作将加速仿制药在澳新地区的市场渗透，为Algorae拓展亚太区域业务奠定坚实基础。随着人口老龄化趋势加剧，心血管与代谢疾病药物市场需求持续增长，此举契合区域医疗健康产业的发展方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"1125866279","title":"Algorae Pharmaceuticals - 簽署協議向澳大利亞市場供應化療藥物卡培他濱","url":"https://stock-news.laohu8.com/highlight/detail?id=1125866279","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125866279?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 06:01","pubTimestamp":1764194483,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals - 签署协议向澳大利亚市场供应化疗药物卡培他滨","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"1150849384","title":"Algorae Pharmaceuticals - 擬議協議下，公司將在澳新市場推出兩款仿製藥及其他產品","url":"https://stock-news.laohu8.com/highlight/detail?id=1150849384","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150849384?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 06:01","pubTimestamp":1760911268,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals - 拟议协议下，公司将在澳新市场推出两款仿制药及其他产品","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"1163905870","title":"Algorae Pharmaceuticals達成協議，將5款仿製腫瘤藥物推向澳大利亞和新西蘭市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1163905870","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163905870?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 06:55","pubTimestamp":1758581719,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals达成协议，将5款仿制肿瘤药物推向澳大利亚和新西兰市场","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/1AI.AU\",params:#limit:6,delay:true,,,undefined,":[]}}